Overview

A Study to Compare SB15 (Proposed Aflibercept Biosimilar) to Eylea in Subjects With Neovascular Age-related Macular Degeneration (AMD)

Status:
Active, not recruiting

Trial end date:
2022-03-24

Target enrollment:

Participant gender:

Summary

This is a randomised, double-masked, parallel group, multicentre study to evaluate the efficacy, safety, PK, and immunogenicity of SB15 compared to Eylea® in subjects with neovascular AMD.

Phase:

Phase 3

Details

Lead Sponsor:

Samsung Bioepis Co., Ltd.

Treatments:

Aflibercept